TransMedics Group (NASDAQ:TMDX) Upgraded to “Buy” at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX) was upgraded by Needham & Company LLC from a “hold” rating to a “buy” rating in a report issued on Thursday, Marketbeat.com reports. The firm presently has a $148.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 23.81% from the stock’s previous close.

Several other equities analysts have also recently commented on the company. Morgan Stanley boosted their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Stifel Nicolaus assumed coverage on TransMedics Group in a research report on Thursday, September 4th. They set a “hold” rating and a $115.00 price target for the company. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 target price on the stock. Zacks Research downgraded shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Eight analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $130.73.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $119.54 on Thursday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of 61.94 and a beta of 2.08. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $145.50. The business’s fifty day moving average is $115.90 and its 200 day moving average is $114.39.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same quarter in the previous year, the firm earned $0.35 EPS. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Research analysts predict that TransMedics Group will post 1 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Opal Wealth Advisors LLC bought a new position in TransMedics Group during the second quarter valued at approximately $26,000. Salomon & Ludwin LLC purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at $28,000. Sound Income Strategies LLC bought a new stake in TransMedics Group in the second quarter worth $48,000. Elevation Point Wealth Partners LLC bought a new stake in TransMedics Group in the second quarter worth $48,000. Finally, Smartleaf Asset Management LLC grew its position in TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after acquiring an additional 135 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.